insulin a-chain

This peptide is a fragment of the alpha-chain of insulin amino acids 1 to 13. The insulin a-chain epitope recognized by human T cells is posttranslationally modified.

Butanoic acid is an endogenous human metabolite, an endogenous histone deacetylase (HDAC) inhibitor. The IC50 of HDAC3, HDAC4 and HDAC1 were 2.4 mM, 4.5 mM and 5.3 mM, respectively. 3-Hydroxybutyric acid has the effects of energy metabolism, neuroprotection, anti-inflammatory, and improvement of insulin resistance.

C16 Ceramide (Cer) (d18:1(14Z)/16:0) is a sphingolipid-derived ceramide composed of long-chain sphingoid base (d18:1) and palmitic acid (C16:0). It serves as a crucial lipid signaling molecule for apoptosis. Specifically, C16 ceramide is involved in cell cycle arrest, cell death, and the inhibition of insulin signaling.

Sulfatides are endogenous sulfoglycolipids with various biological activities in the central and peripheral nervous systems, pancreas, and immune system. They are produced from the combination of ceramide and UDP-galactose in the endoplasmic reticulum followed by sulfation in the Golgi apparatus. The ceramide portion contains variable fatty acid chain lengths, which are tissue- and pathology-dependent. Sulfatides are primarily found in the myelin sheath of oligodendrocytes and Schwann cells, with smaller chain lengths predominant during development and longer chain lengths predominant in mature cells. They accumulate in the lysosome of patients with metachromatic leukodystrophy, a disorder characterized by arylsulfatase A deficiency. Sulfatides are also located in pancreatic β-cells and inhibit insulin release from isolated rat pancreatic islet cells, suggesting a potential role in diabetes. Sulfatides can induce inflammation in glia in vitro and certain sulfatides, such as C24:1 3'-sulfo-galactosylceramide, can induce an immune response in vitro in mouse splenocytes. Sulfatides (bovine) (sodium salt) is a mixture of isolated bovine sulfatides.

Insulin efsitora alfa (LY-3209590) is a selective insulin receptor (IR) agonist and fusion protein that combines a novel single-chain insulin variant with the structural domain of human IgG Fc for the study of type 2 diabetes.

Insulin Aspart is a rapid-acting insulin analog generated by substituting proline with aspartic acid at position B28 of the human insulin B chain. After subcutaneous administration, it exhibits faster absorption and onset of action compared with regular human insulin, thereby improving postprandial glycemic control. It is commonly used in diabetes research and therapy.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are lipids influenced by dietary changes, playing a crucial role in insulin sensitivity. These compounds typically consist of a C-16 or C-18 fatty acid (for example, palmitoleic, palmitic, oleic, or stearic acid) linked to a hydroxy fatty acid with the same carbon chain length. 13-PAHSA, a derivative where palmitic acid is esterified to 13-hydroxy stearic acid, is notably prevalent in the adipose tissue of glucose-tolerant AG4OX mice, which exhibit enhanced glucose transport via the overexpression of the Glut4 glucose transporter. This observation, along with the metabolic benefits seen from other FAHFAs—including improved glucose tolerance, stimulated insulin secretion, and anti-inflammatory properties—suggests that 13-PAHSA may function as a bioactive lipid beneficial in managing metabolic syndrome and inflammation.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids that are influenced by fasting and high-fat diets and linked to improved insulin sensitivity in mice. These compounds typically feature a chain of either 16 or 18 carbon atoms (for example, palmitoleic, palmitic, oleic, or stearic acid) esterified with a hydroxy fatty acid chain of similar length. One specific FAHFA, known as 5-OAHSA, consists of oleic acid bonded to the fifth carbon of hydroxy stearic acid. Within the FAHFA family, OAHSAs exhibit the highest serum levels in AG4OX mice, which are known for their glucose tolerance attributed to the overexpression of the Glut4 glucose transporter in adipose tissue.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are recent discoveries in endogenous lipids that are influenced by dietary changes such as fasting and high-fat diets, showing a link with enhanced insulin sensitivity in mice. These compounds typically feature a C-16 or C-18 fatty acid (e.g., palmitoleic, palmitic, oleic, or stearic acid) bound to a hydroxy group on another C-16 or C-18 fatty chain. A specific FAHFA, 9-POHSA, consists of palmitoleic acid connected at the hydroxy stearic acid's 9th position. This molecule, in particular, exhibits notably increased levels in the serum of glucose-tolerant AG4OX mice, which express the Glut4 glucose transporter predominantly in their adipose tissue. Given the broader family of FAHFAs' roles in enhancing glucose tolerance, promoting insulin secretion, and exerting anti-inflammatory effects, 9-POHSA emerges as a potential bioactive lipid involved in managing metabolic syndrome and inflammation.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) have emerged as significant regulators of metabolic processes, influenced by dietary changes such as fasting and high-fat diets, and are linked to improved insulin sensitivity in mice. These compounds typically feature a fatty acid chain, either C-16 or C-18 in length (for example, palmitoleic, palmitic, oleic, or stearic acid), esterified to a hydroxy fatty acid of similar length. A specific FAHFA, 12-POHSA, involves the esterification of palmitoleic acid to the 12th carbon of stearic acid. Notably, 12-POHSA levels are markedly higher in the serum of AG4OX mice, which exhibit enhanced glucose tolerance due to overexpression of the Glut4 glucose transporter in adipose tissue. Given the capacity of FAHFAs to enhance glucose tolerance, stimulate insulin secretion, and exert anti-inflammatory actions, 12-POHSA holds potential as a bioactive lipid implicated in managing metabolic syndrome and inflammation.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are recently discovered lipids that play a role in the body's response to fasting and high-fat diets, with a link to insulin sensitivity. These compounds consist of a long-chain fatty acid (such as palmitoleic, palmitic, oleic, or stearic acid) bonded to a hydroxy fatty acid, both ranging in length from C-16 to C-18. Specifically, 12-OAHSA is a type of FAHFA where oleic acid is attached to the 12th carbon of hydroxy stearic acid. Within the FAHFA family, OAHSAs are particularly notable for their high concentration in the serum of AG4OX mice, a strain engineered to express the Glut4 glucose transporter predominantly in their adipose tissue, which demonstrates an enhanced glucose tolerance.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are lipids that are modulated by dietary changes such as fasting and high-fat diets, and they play a role in insulin sensitivity. These compounds generally consist of a fatty acid chain of either 16 or 18 carbons (for example, palmitoleic, palmitic, oleic, or stearic acid) esterified to a similarly long hydroxy fatty acid. One specific FAHFA, 9-SAHSA, features stearic acid esterified at the 9th carbon of hydroxy stearic acid. The concentration of 9-SAHSA is notably increased in the serum of glucose-tolerant AG4OX mice, which specifically express the Glut4 glucose-transporting protein in adipose tissue.

ELOVL6-IN-4 is a potent and selective ELOVL6 inhibitor (IC50 = 36 nM). It improves lipid metabolism and insulin sensitivity by reducing LCFA synthesis in obesity and NASH research.

Stearic acid-18,18,18-d3 is a deuterated analog of stearic acid. Stearic acid is a long-chain saturated fatty acid found in many animal and vegetable fats and oils.

InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7.

Human proinsulin, the single-chain peptide precursor of insulin, consists of the insulin A and B chains connected by the 31 amino acid C-peptide. Cleavage of proinsulin by proteolytic enzymes produces insulin and free C-peptide.

LAGIPRA peptide is a long-acting agonist of GIP1R. It improves insulin sensitivity by enhancing glucose handling and reduces circulating branched-chain amino acids (BCAA) and keto acids. LAGIPRA peptide holds potential for research in type 2 diabetes.

LAGIPRA peptide TFA is a long-acting GIP1R agonist. It improves insulin sensitivity by enhancing glucose processing and reducing circulating branched-chain amino acids (BCAA) and keto acids. LAGIPRA peptide TFA shows potential for research in type 2 diabetes.